Literature DB >> 3292038

Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects.

J Kewenter1, S Björk, E Haglind, L Smith, J Svanvik, C Ahrén.   

Abstract

All inhabitants of the city of Göteborg who in 1982 were between 60 and 64 years of age (27,700) were randomly divided into a test and a control group. The 13,759 subjects in the test group were invited to perform Hemoccult II (Smith Kline Diagnostic, Sunnyvale, CA) fecal occult blood testing over 3 days and to repeat the testing after 16 to 22 months. At the first screening 9,040 (66%) completed the test, and 7,770 (58%) completed the test at the second screening. In the first screening the test group was divided into two subgroups in which the tests were rehydrated and unhydrated before development. All tests were rehydrated in the second screening; 1.9% and 5.8% of the tests were positive in the unhydrated and rehydrated subgroups, respectively. The number of diagnosed neoplasms in the first screening was significantly larger (P less than 0.01) in the rehydrated group compared to the unhydrated group, 50 and 24 neoplasms, respectively. Sixteen of 61 carcinomas in the test group were found in the interval between the two screenings, 19 of the carcinomas at the second screening, and ten among the nonresponders. Rehydration of the Hemoccult II test is a necessity. Significantly more carcinomas (61) were found in the test group compared to the control group (20). There was a trend toward favorable tumor staging in the test group compared to the control group.

Entities:  

Mesh:

Year:  1988        PMID: 3292038     DOI: 10.1002/1097-0142(19880801)62:3<645::aid-cncr2820620333>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Colorectal cancer screening. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

2.  [Staging of colorectal cancer. Official recommendations of the Canadian Study Group on Preventive Medicine].

Authors: 
Journal:  Can Fam Physician       Date:  2001-09       Impact factor: 3.275

3.  Colorectal cancer screening. Recommendation statement from the Canadian task force on preventive health care.

Authors: 
Journal:  Can Fam Physician       Date:  2001-09       Impact factor: 3.275

4.  [Conventional and molecular screening (fecal tests)].

Authors:  C Pox; K Schulmann; W Schmiegel
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

5.  Current awareness in Canada of clinical practice guidelines for colorectal cancer screening.

Authors:  Tracey K Asano; Daniel Toma; Hartley S Stern; Robin S McLeod
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

Review 6.  Cancer screening in renal transplant recipients: what is the evidence?

Authors:  Germaine Wong; Jeremy R Chapman; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

7.  Detecting colorectal cancer with a large scale fecal occult blood testing program.

Authors:  D I Gregorio; P Lolachi; H Hansen
Journal:  Public Health Rep       Date:  1992 May-Jun       Impact factor: 2.792

8.  A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.

Authors:  B Towler; L Irwig; P Glasziou; J Kewenter; D Weller; C Silagy
Journal:  BMJ       Date:  1998-08-29

9.  Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer.

Authors:  S J Winawer; D J St John; J H Bond; P Rozen; R W Burt; J D Waye; O Kronborg; M J O'Brien; D T Bishop; R C Kurtz
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

10.  A simple strategy to improve patient adherence to outpatient fecal occult blood testing.

Authors:  J D Freedman; C K Mitchell
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.